Shamburg News · 8-K filed Nov 12, 2026, 4:17 PM EST
ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights
PROK · PROKIDNEY CORP.
- Earnings
- Materiality: high
ProKidney Corp. reported financial results for the quarter ended September 30, 2026, including a net loss before noncontrolling interest of $51.8 million and research and development expenses of $40.8 million. Basic and diluted net loss per Class A share was $(0.17). The company reported cash, cash equivalents and marketable securities of $141.9 million as of September 30, 2026, and said it expects to complete PROACT 1 enrollment in Q1 2027 and report topline eGFR slope results in Q2 2027.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-458470.
Written from the filing by Shamburg Markets. Figures are as reported by the company.